Skip to main content

Robb Gary Charles's Form 4 filing

Corcept Therapeutics Inc (CORT) · filed May 19, 2022

Accession no.
0000899243-22-018862
Filed
May 19, 2022
Trade date
May 17-19, 2022
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 3 non-derivative transactions. Open-market sales total $684.4K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Robb Gary CharlesCIK 0001529655Officer (Chief Business Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
May 17, 2022Common StockSSaleDisposed−28,745$19.55−$561,964.7542,701Direct
May 18, 2022Common StockSSaleDisposed−128$19.55−$2,502.442,573Direct
May 19, 2022Common StockSSaleDisposed−6,127$19.57F1−$119,905.3936,446Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $19.55 to $19.63. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)